Microfinance: Business, Profitability, and the Creation of Social Value

Michael  Chu

Chapter | Business Solutions for the Global Poor: Creating Social and Economic Value | 2007

Microfinance: Business, Profitability, and the Creation of Social Value

Abstract

The chapter examines the development of microfinance from its NGO origins to the present stage in which it is characterized by regulated commercial institutions capable of superior financial returns. It then looks at the creation of social value under these circumstances, advancing a role for profit in the generation of social value. In the process, it sets forth the conditions under which profit is positive and when it is negative from a societal perspective, and why business at the base of the pyramid may matter.

Keywords: Microfinance; Investment Return; Profit; Governing Rules, Regulations, and Reforms; Social Enterprise; Non-Governmental Organizations; Perspective; Value Creation;

Format: Print

Citation:

Chu, Michael. "Microfinance: Business, Profitability, and the Creation of Social Value." Chap. 28 in Business Solutions for the Global Poor: Creating Social and Economic Value, by V. Kasturi Rangan, John A. Quelch, Gustavo Herrero, and Brooke Barton, 309–320. John Wiley & Sons, 2007.

After long dominating Mexican microfinance, Compartamos Banco faces the emergence of fintech, just as for the first time its loan portfolio and clients have declined. Enrique Majós, CEO of GENTERA, the bank´s parent company, is keenly aware of the profound changes since the Compartamos IPO in April 2007, when it was valued at $1.5 billion and became the first bank wholly dedicated to microfinance to be quoted in a major stock exchange. Since then, the market has become intensely competitive, with both large established institutions and new entrants vying for the same customers. Simultaneously, the digital era has spawned fintech, threatening to disrupt Compartamos’ highly successful model but also providing opportunities for the bank to reshape it. While challenged to manage key innovation within a leading incumbent, Majós must consider whether to commit his team to a major cost reduction in the next few years to his board of directors at their next meeting at the end of the month.

With a breakthrough cure for Hepatitis C listing in the U.S. at $1,000/pill, Gilead must now solve the issue of making it available to patients across the world, much as it did for its blockbuster HIV/AIDS antiretrovirals. For Erik Musalem, the new general manager of Gilead Mexico, the challenge was complicated by operating in a middle-income country, where Gilead’s terms for more vulnerable nations did not apply. For all practical purposes, Musalem had only one customer for his company’s Hep C medicine: Mexico’s public health system and the National Pricing Commission that set prices annually for the entire sector. With no lack of priorities competing for the finite resources of the public health sector, Musalem’s charge was to devise the strategy that in the long run would maximize access to the cure in Mexico while protecting the financial strength of Gilead Sciences, Inc.

Faculty & Research

Microfinance: Business, Profitability, and the Creation of Social Value

Abstract

Citation:

About the Author

More from the Author